Neurocrine Biosciences (NBIX) Misses Q1 EPS by 16c

Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of ($0.90), $0.16 worse than the analyst estimate of ($0.74). Non revenues reported.

"The Company did not report any revenue for the first quarter of 2017 compared to $15.0 million of revenue for the first quarter of 2016, which represented a milestone payment from AbbVie related to the commencement of Phase III studies of elagolix in uterine fibroids.."

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary